Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2004 1
2006 2
2007 1
2008 1
2009 1
2018 1
2019 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS, Lebrec J, Dib A, Heitmann E, Federici MO, Yu M, Sapin H, Barrett A, Guerci B, Giorgino F, Füchtenbusch M, García-Pérez LE. Boye KS, et al. Among authors: federici mo. Diabetes Obes Metab. 2023 Dec;25(12):3453-3464. doi: 10.1111/dom.15145. Epub 2023 Sep 15. Diabetes Obes Metab. 2023. PMID: 37712754
Closing the loop: the adicol experience.
Hovorka R, Chassin LJ, Wilinska ME, Canonico V, Akwi JA, Federici MO, Massi-Benedetti M, Hutzli I, Zaugg C, Kaufmann H, Both M, Vering T, Schaller HC, Schaupp L, Bodenlenz M, Pieber TR. Hovorka R, et al. Among authors: federici mo. Diabetes Technol Ther. 2004 Jun;6(3):307-18. doi: 10.1089/152091504774197990. Diabetes Technol Ther. 2004. PMID: 15198833
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B, Giorgino F, Sapin H, Boye K, Lebrec J, Federici MO, Heitmann E, Dib A, Füchtenbusch M, García-Pérez LE. Guerci B, et al. Among authors: federici mo. Diabetes Obes Metab. 2022 Dec;24(12):2373-2382. doi: 10.1111/dom.14823. Epub 2022 Aug 31. Diabetes Obes Metab. 2022. PMID: 35876235 Free PMC article.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE, Boye KS, Rosilio M, Jung H, Heitmann E, Norrbacka K, Federici MO, Gentilella R, Guerci B, Giorgino F, Aigner U, Sapin H. García-Pérez LE, et al. Among authors: federici mo. Diabetes Ther. 2021 Jul;12(7):1929-1946. doi: 10.1007/s13300-021-01076-0. Epub 2021 Jun 7. Diabetes Ther. 2021. PMID: 34097244 Free PMC article.
Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
Boye KS, Matza LS, Stewart KD, Jordan J, Biricolti G, Del Santo S, Perez-Nieves M, Federici MO, Gentilella R, Losi S, Norrbacka K. Boye KS, et al. Among authors: federici mo. J Med Econ. 2019 Aug;22(8):806-813. doi: 10.1080/13696998.2019.1609482. Epub 2019 May 17. J Med Econ. 2019. PMID: 31010349 Free article.
Privacy impact assessment in the design of transnational public health information systems: the BIRO project.
Di Iorio CT, Carinci F, Azzopardi J, Baglioni V, Beck P, Cunningham S, Evripidou A, Leese G, Loevaas KF, Olympios G, Federici MO, Pruna S, Palladino P, Skeie S, Taverner P, Traynor V, Benedetti MM. Di Iorio CT, et al. Among authors: federici mo. J Med Ethics. 2009 Dec;35(12):753-61. doi: 10.1136/jme.2009.029918. J Med Ethics. 2009. PMID: 19948932
14 results